Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Rethinking Palpable Adenopathy as a Marker of High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.

    Article  Google Scholar 

  2. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–26.

    Article  Google Scholar 

  3. Petruolo OA, Pilewskie M, Patil S, et al. Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24(9):2556–62.

    Article  Google Scholar 

  4. Montagna G, Sevilimedu V, Fornier M, Jhaveri K, Morrow M, Pilewskie ML. How effective is neoadjuvant endocrine therapy (net) in downstaging the axilla and achieving breast-conserving surgery? Ann Surg Oncol. 2020;27(12):4702–10.

    Article  Google Scholar 

  5. Crown A, Sevilimedu V, Morrow M. Palpable adenopathy does not indicate high-volume axillary nodal disease in hormone receptor–positive breast cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09943-7.

    Article  PubMed  Google Scholar 

  6. Kalinsky K, Barlow WE, Meric-Bernstam F, et al. SWOG S1007: adjuvant trial randomized ER+ patients who had a recurrence score < 25 and 1–3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy. Abstract GS3-00. Paper presented at: 2020 Virtual San Antonio Breast Cancer Symposium2020; Virtual.

Download references

Author information

Authors and Affiliations

  1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Angelena Crown MD & Monica Morrow MD

Authors
  1. Angelena Crown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Morrow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica Morrow MD.

Ethics declarations

Disclosures

Monica Morrow has received honoraria from Genomic Health. Angelena Crown has no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crown, A., Morrow, M. ASO Author Reflections: Rethinking Palpable Adenopathy as a Marker of High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol 28, 6069–6070 (2021). https://doi.org/10.1245/s10434-021-09984-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09984-y

Search

Navigation